Drugs / QLS-111
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07354477 | Feb → Sep 2026 expected | diabetic retinopathy, low tension glaucoma | Qlaris Bio, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06030193 | Aug 2025 → Feb 2026 | low tension glaucoma | Qlaris Bio, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06249152 | Apr → Dec 2024 | ocular hypertension, open-angle glaucoma | Qlaris Bio, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06016972 | Mar → Aug 2024 | ocular hypertension, open-angle glaucoma | Qlaris Bio, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS-111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06030193 ↗ |
| Route | Other | “QLS-111 ophthalmic solution 0.015% applied QPM OU” NCT06030193 ↗ |